Compare · DFTX vs MTEX
DFTX vs MTEX
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Mannatech Incorporated (MTEX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and MTEX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.64B, about 251.5x MTEX ($10.5M).
- Over the past year, DFTX is up 259.9% and MTEX is down 51.8% - DFTX leads by 311.7 points.
- DFTX has been more active in the news (10 items in the past 4 weeks vs 6 for MTEX).
- DFTX has more recent analyst coverage (4 ratings vs 0 for MTEX).
PerformanceDFTX+259.91%MTEX-51.83%
2025-06-17+0.00%2026-06-16
- Company
- Definium Therapeutics Inc.
- Mannatech Incorporated
- Price
- $24.15+1.62%
- $5.40+0.84%
- Market cap
- $2.64B
- $10.5M
- 1M return
- +15.11%
- +21.21%
- 1Y return
- +259.91%
- -51.83%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 10
- 6
- Recent ratings
- 4
- 0
MTEX
Mannatech Incorporated
Mannatech, Incorporated operates as a health and wellness company worldwide. It develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management products. The company primarily sells its products directly, as well as through network marketing channels and a website. Mannatech, Incorporated was founded in 1993 and is headquartered in Flower Mound, Texas.
Latest DFTX
- SEC Form S-8 filed by Definium Therapeutics Inc.
- Director Vallone Carol A was granted 4,666 shares, increasing direct ownership by 28% to 21,210 units (SEC Form 4)
- Director Crystal Roger was granted 4,666 shares, increasing direct ownership by 24% to 24,289 units (SEC Form 4)
- Director Gryska David W was granted 4,666 shares, increasing direct ownership by 31% to 19,900 units (SEC Form 4)
- Director Adsett Roger was granted 3,555 shares (SEC Form 4)
- Director Krebs Andreas was granted 4,666 shares, increasing direct ownership by 31% to 19,773 units (SEC Form 4)
- Director Bruhn Suzanne Louise was granted 4,666 shares, increasing direct ownership by 24% to 24,289 units (SEC Form 4)
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Definium Therapeutics Announces New Employee Inducement Grants
Latest MTEX
- Mannatech Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Mannatech Announces Appointment of Yasir Haider as Chief Financial Officer
- SEC Form 4 filed by Director Toth Robert
- SEC Form 4 filed by Director John Seifrick A
- Mannatech Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Mannatech Announces Results of Annual Shareholders' Meeting
- Director Jobe Larry A bought $11,548 worth of shares (2,803 units at $4.12), increasing direct ownership by 4% to 70,000 units (SEC Form 4)
- Director Jobe Larry A bought $21,000 worth of shares (5,000 units at $4.20), increasing direct ownership by 8% to 67,197 units (SEC Form 4)
- Director Robbins Kevin Andrew bought $29,607 worth of shares (7,100 units at $4.17), increasing direct ownership by 27% to 33,333 units (SEC Form 4)
- Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits